Trial Search Results
PCSK9 Inhibition After Heart Transplantation
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.
Stanford is currently accepting patients for this trial.
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Biological: alirocumab
- Biological: placebo
- Heart Transplant recipient
- impaired liver function
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study